Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,950.00
(
0.90%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,320.56
(
0.16%
)
News Focus
News Focus
Post# of 257483
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122925
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 226231

Wednesday, 09/25/2019 5:37:10 PM

Wednesday, September 25, 2019 5:37:10 PM

Post# of 257483
ENTA—After listening to the CC and further contemplating the EDP-305 dataset reported today, I think ENTA should strongly consider switching from EDP-305 to the company's backup FXR compound.

EDP-305's pruritis rate at 2.5mg is too high, and it's unclear whether there's a bona fide therapeutic window for this drug.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today